Rolapitant

Drug Profile

Rolapitant

Alternative Names: Rolapitant hydrochloride; SCH-619734; VARUBI; Varuby

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; Schering-Plough; TESARO
  • Class Antiemetics; Ethers; Piperidines; Pyrrolidines; Small molecules; Spiro compounds
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting
  • Discontinued Cough; Postoperative nausea and vomiting

Most Recent Events

  • 28 Nov 2017 Launched for Chemotherapy induced nausea and vomiting (Combination therapy, Prevention) in USA (IV)
  • 25 Oct 2017 Registered for Chemotherapy induced nausea and vomiting (Prevention, Combination therapy) in USA (IV, Infusion)
  • 25 Oct 2017 Tesaro announces intention to launch IV rolapitant in Chemotherapy induced nausea and vomiting (Combination therapy, Prevention) in USA in November 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top